Blood and marrow stem cells transplantation in multiple sclerosis. Present and future in its use and selection of patients

Multiple sclerosis (MS) is a disease with an autoinmune pathophysiology. A new and promising treatment in this group of patients is the blood and marrow stem cells transplant at ion which is currently an experimental treatment with evident immuno-suppressant effects. It has not been demonstrated any effect on neurodegeneration and it is preferred to use this procedure as a non-conventional treatment of multiple sclerosis. Select ion of patients should be strict, mainly in patients with moderate severity and an important inflammatory component. It is not a rescue treatment because its utility in progressive forms or advanced MS has not been demonstrated and the risk is high. This review includes an analysis of the current protocols and their results.